Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ZBIO
Stock Latest News
Ratings
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating
4d ago
ZBIO
Premium
Ratings
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed
5d ago
ZBIO
Premium
The Fly
Zenas BioPharma files automatic mixed securities shelf
5d ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Secures Licensing Deal with InnoCare
6d ago
8K
ZBIO
Premium
The Fly
Zenas BioPharma to sell 6.3M shares at $19.00 in private placement
6d ago
ZBIO
Premium
The Fly
Zenas BioPharma, InnoCare Pharma announce orelabrutinib license agreement
6d ago
ZBIO
Premium
Ratings
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential
1M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Secures $300M Funding for Obexelimab
1M ago
8K
ZBIO
Premium
The Fly
Zenas BioPharma, Royalty Pharma enter obexelimab funding agreement
1M ago
RPRX
ZBIO
Premium
The Fly
Royalty Pharma, Zenas BioPharma enter into obexelimab funding agreement
1M ago
RPRX
ZBIO
Premium
Ratings
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence
2M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit
2M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Reports Q2 2025 Financial Results
2M ago
ZBIO
Premium
Ratings
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating
2M ago
ZBIO
Premium
The Fly
Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year
2M ago
ZBIO
Premium
The Fly
Zenas BioPharma expects cash to fund operations into Q4 of 2026
2M ago
ZBIO
Premium
The Fly
Sixteen new option listings on July 23rd
3M ago
RAL
SMU
Premium
Ratings
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
3M ago
ZBIO
Premium
The Fly
Zenas BioPharma assumed with an Overweight at Morgan Stanley
3M ago
ZBIO
Premium
Ratings
Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
3M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Announces Board Changes at Annual Meeting
4M ago
8K
ZBIO
Premium
Company Announcements
Zenas BioPharma to Present at Jefferies Conference
4M ago
8K
ZBIO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
